Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,841 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 822 · Balance 37,297 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 2 · 2026-09-15 · Exercise / conversion · Acquired 1,019 · Balance 38,316 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 3 · 2026-09-15 · Exercise / conversion · Acquired 2,255 · Balance 40,571 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. Row 4 · 2026-09-15 · Sale · Disposed 4,730 · Balance 35,841 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.52 · Expires 2029-11-20 | Direct | 6,574 |
Reported balance
After 2026-09-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-15 · Exercise / conversion · Disposed 822 · Balance 6,574 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2033-05-31 | Direct | 8,144 |
Reported balance
After 2026-09-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-15 · Exercise / conversion · Disposed 1,019 · Balance 8,144 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2034-06-14 | Direct | 18,032 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 2,255 · Balance 18,032 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. F2: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.
F2: The option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2025 Filed Aug 5, 2025 22:28 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 6,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-25-000115 · wk-form4_1754432914.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:25 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 9,208 | $13.84 | $127,430.43 |
DisclosureSEC source: 0001787306-25-000101 · wk-form4_1751487930.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,206 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.65 to $13.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:32 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,139 | $13.37 | $135,573.64 |
DisclosureSEC source: 0001787306-25-000099 · wk-form4_1750451534.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,414 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.2118 to $13.59, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 20,568 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0002065881-25-000028 · wk-form4_1750119471.xml · derivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,568 Underlying: Common Stock · 20,568 shares Expires 2035-06-12 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 7,609 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000028 · wk-form4_1750119471.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,553 F1 · shares: Represents restricted stock units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:49 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $14.64 | $146,357.00 |
DisclosureSEC source: 0001787306-25-000077 · wk-form4_1746478168.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,944 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 5, 2024, by the Reporting Person, with a plan end date of May 30, 2025. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.19 to $14.95, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $15.12 | $151,236.00 |
DisclosureSEC source: 0001787306-25-000054 · wk-form4_1743711673.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,944 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 5, 2024, by the Reporting Person, with a plan end date of May 30, 2025. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.83 to $15.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:43 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $13.00 | $130,048.00 |
DisclosureSEC source: 0001787306-25-000040 · wk-form4_1741135403.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,944 F1 · shares: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 5, 2024, by the Reporting Person, with a plan end date of May 30, 2025. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.68 to $13.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 01:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $12.71 | $127,100.00 |
DisclosureSEC source: 0001787306-25-000015 · wk-form4_1738717253.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,944 F1 · shares: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 5, 2024, by the Reporting Person, with a plan end date of May 30, 2025. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.56 to $13.02, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:08 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $14.67 | $146,714.00 |
DisclosureSEC source: 0001787306-25-000002 · wk-form4_1736197683.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,944 F1 · shares: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 5, 2024, by the Reporting Person, with a plan end date of May 30, 2025. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.16 to $15.11, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 21:16 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $12.51 | $125,133.00 |
DisclosureSEC source: 0001787306-24-000167 · wk-form4_1733260600.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,944 F1 · shares: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 5, 2024, by the Reporting Person, with a plan end date of May 30, 2025. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.37 to $13.00, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:46 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $8.65 | $86,541.00 |
DisclosureSEC source: 0001787306-24-000143 · wk-form4_1730843155.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,944 F1 · shares: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.4493 to $8.82, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:55 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $9.26 | $92,616.00 |
DisclosureSEC source: 0001787306-24-000137 · wk-form4_1727988938.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,944 F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $9.22 to $9.4138, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $10.77 | $107,695.00 |
DisclosureSEC source: 0001787306-24-000131 · wk-form4_1725573381.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,944 F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $10.67 to $10.865, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: The total shares reported in Column 5 includes shares held in a revocable living trust that previously were reported indirectly. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 6,614 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-24-000115 · wk-form4_1722890217.xml · derivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,614 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,386 | $9.87 | $33,418.47 |
DisclosureSEC source: 0001787306-24-000115 · wk-form4_1722890217.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,953 F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $9.76 to $10.08, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,614 | $9.87 | $65,277.53 |
DisclosureSEC source: 0001787306-24-000115 · wk-form4_1722890217.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,339 F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $9.76 to $10.08, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:37 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 6,614 | $1.68 | $11,115.49 |
DisclosureSEC source: 0001787306-24-000115 · wk-form4_1722890217.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 23:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 4,319 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-24-000108 · wk-form4_1719961990.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,614 Underlying: Common Stock · 4,319 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 23:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 5,681 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-24-000108 · wk-form4_1719961990.xml · derivative · entry 5 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,681 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 23:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 10,000 | $9.31 | $93,141.00 |
DisclosureSEC source: 0001787306-24-000108 · wk-form4_1719961990.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,339 Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 23:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 4,319 | $1.68 | $7,258.51 |
DisclosureSEC source: 0001787306-24-000108 · wk-form4_1719961990.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 23:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 5,681 | $1.68 | $9,547.49 |
DisclosureSEC source: 0001787306-24-000108 · wk-form4_1719961990.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 27,052 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001787306-24-000105 · wk-form4_1718743938.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,052 Underlying: Common Stock · 27,052 shares Expires 2034-06-14 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:52 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 10,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000105 · wk-form4_1718743938.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,339 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 6,458 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-24-000087 · wk-form4_1717704925.xml · derivative · entry 7 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,458 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 3,542 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-24-000087 · wk-form4_1717704925.xml · derivative · entry 6 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,681 Underlying: Common Stock · 3,542 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,458 | $8.01 | $51,755.70 |
DisclosureSEC source: 0001787306-24-000087 · wk-form4_1717704925.xml · nonDerivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,200 F1 · price: The transaction was executed in multiple trades in prices ranging from $8.00 to $8.155, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,542 | $8.00 | $28,336.00 |
DisclosureSEC source: 0001787306-24-000087 · wk-form4_1717704925.xml · nonDerivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,658 Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 6,458 | $1.68 | $10,853.31 |
DisclosureSEC source: 0001787306-24-000087 · wk-form4_1717704925.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:15 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 3,542 | $1.68 | $5,952.69 |
DisclosureSEC source: 0001787306-24-000087 · wk-form4_1717704925.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:54 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 12,220 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001787306-23-000050 · wk-form4_1685746466.xml · derivative · entry 3 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,220 Underlying: Common Stock · 12,220 shares Expires 2033-05-31 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:54 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000050 · wk-form4_1685746466.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,200 F1 · balance_after: Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 23:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-23-000036 · wf-form4_168185882846729.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,458 Underlying: Common Stock · 8,500 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 23:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 8,500 | $13.97 | $118,728.00 |
DisclosureSEC source: 0001787306-23-000036 · wf-form4_168185882846729.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,825 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.76 to $14.20, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 23:00 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 8,500 | $1.68 | $14,285.10 |
DisclosureSEC source: 0001787306-23-000036 · wf-form4_168185882846729.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 20:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-23-000027 · wf-form4_168115758269324.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,958 Underlying: Common Stock · 8,500 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 20:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 8,500 | $12.01 | $102,085.00 |
DisclosureSEC source: 0001787306-23-000027 · wf-form4_168115758269324.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,825 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.035, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 20:13 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 8,500 | $1.68 | $14,285.10 |
DisclosureSEC source: 0001787306-23-000027 · wf-form4_168115758269324.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 15, 2023 Filed Feb 21, 2023 12:20 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-23-000010 · wf-form4_167698204256036.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,458 Underlying: Common Stock · 8,500 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| February 15, 2023 Filed Feb 21, 2023 12:20 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 8,500 | $16.98 | $144,352.10 |
DisclosureSEC source: 0001787306-23-000010 · wf-form4_167698204256036.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,825 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $16.84 to $17.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 15, 2023 Filed Feb 21, 2023 12:20 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 8,500 | $1.68 | $14,285.10 |
DisclosureSEC source: 0001787306-23-000010 · wf-form4_167698204256036.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 01:18 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-23-000004 · wf-form4_167409108112700.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,958 Underlying: Common Stock · 8,500 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 01:18 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 8,500 | $13.72 | $116,654.85 |
DisclosureSEC source: 0001787306-23-000004 · wf-form4_167409108112700.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,825 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 01:18 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 8,500 | $1.68 | $14,280.00 |
DisclosureSEC source: 0001787306-23-000004 · wf-form4_167409108112700.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 1,020 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001787306-22-000075 · wf-form4_166872057856154.xml · derivative · entry 4 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,458 Underlying: Common Stock · 1,020 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: The option began vesting on March 13, 2019 and will vest monthly over a four year period, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 3,403 | $20.01 | $68,102.54 |
DisclosureSEC source: 0001787306-22-000075 · wf-form4_166872057856154.xml · nonDerivative · entry 2 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,825 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 8,812 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 21:29 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 1,020 | $1.68 | $1,713.60 |
DisclosureSEC source: 0001787306-22-000075 · wf-form4_166872057856154.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 8,812 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 20:26 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,000 | $20.29 | $121,766.40 |
DisclosureSEC source: 0001567619-22-018322 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,208 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $20.06 to $20.53, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 8,812 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:06 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 6,000 | $24.80 | $148,788.60 |
DisclosureSEC source: 0001567619-22-016413 · doc1.xml · nonDerivative · entry 1 Welgus Howard G. · CIK 0001801050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,208 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $24.51 to $25.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 8,812 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.